Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
[Preprint]. 2025 Nov 28:2025.11.26.25340699.
doi: 10.1101/2025.11.26.25340699.

HIV Remains a Risk Factor for Unfavorable Tuberculosis Treatment Outcomes in the Era of Universal Access to Antiretroviral Therapy in Botswana

Affiliations

HIV Remains a Risk Factor for Unfavorable Tuberculosis Treatment Outcomes in the Era of Universal Access to Antiretroviral Therapy in Botswana

Azadeh Baniasad et al. medRxiv. .

Abstract

Botswana implemented its universal "Treat All" antiretroviral therapy (ART) policy in 2016, expanding treatment eligibility to all people living with HIV (PLHIV). HIV has been known to be a leading risk factor for tuberculosis (TB) and poor TB treatment outcomes. The primary goal of this study is to assess whether HIV infection and HIV-associated immunosuppression remain risk factors for unfavorable TB treatment outcomes in the Post-Treat All era. We analyzed 636 TB patients treated in Gaborone (2017-2023), of whom 54.4% were HIV-positive. Unfavorable outcomes (death, failure, or loss to follow-up) occurred in 19.7% of HIV-positive and 8.5% of HIV-negative patients. We used logistic regression to estimate unadjusted and covariate-adjusted associations between TB treatment outcome and HIV status and between TB treatment outcome and CD4+ T-cell count. HIV-positive patients had 2.5-fold higher odds of unfavorable outcomes compared with HIV-negative patients [adjusted OR: 2.51, 95% CI: (1.48, 4.38)], controlling for age, sex, TB history, distance to clinic, substance use, and occupational status. PLHIV with CD4+ T-cell < 200 cells / μ L was associated with approximately three-fold higher odds of unfavorable outcomes compared with HIV-negative participants [OR: 3.12, 95% CI: (1.65, 5.97)]. The secondary goal was to test whether the HIV effect changed following Treat All implementation. We combined the data from 2017-2023 with a Pre-Treat All cohort (2012-2016, n= 233, HIV prevalence 60.8%) and fit a frequentist logistic regression and Bayesian mixed-effects models with an interaction term that allows treatment era (Pre- vs. Post-Treat All) to modify the effect of HIV on TB treatment outcome. The estimated change in the HIV effect was uncertain [relative OR: 0.41; 95% CI: (0.11, 1.55)]. Combining the two Botswana data sets with 12 Pre- and Post-Treat All studies from neighboring Ethiopia showed that the pooled effect of HIV infection on unfavorable TB outcome has increased in the Post-Treat All period [relative OR: 2.39; 95% BCI: (1.36, 3.34)].

PubMed Disclaimer

Figures

Figure 1:
Figure 1:
Flow chart showing data cleaning steps and sample sizes for analysis datasets.

References

    1. Karim Salim Abdool. Botswana’s progress toward achieving the 2020 unaids 90-90-90 targets. The Lancet HIV, 3(5):e195–e196, 2016. doi: 10.1016/S2352-3018(16)30037-0. Published May 2016; accessed 7 August 2025. - DOI - PubMed
    1. Adeyi A. A. and Oyeleke P.. Heavy metals and polycyclic aromatic hydrocarbons in soil from e-waste dumpsites in lagos and ibadan, nigeria. Journal of Health & Pollution, 7(15):71–84, 2017. doi: 10.5696/2156-9614-7.15.71. Accessed 7 August 2025. - DOI
    1. Alayu Alemu Mikias, Yesuf Aman, Girma Fikirte, Adugna Fanna, Melak Kumlachew, Biru Mengistu, Seyoum Melaku, and Abiye Tesfahun. Impact of hiv-aids on tuberculosis treatment outcome in southern ethiopia–a retrospective cohort study. Journal of clinical tuberculosis and other mycobacterial diseases, 25:100279, 2021. - PMC - PubMed
    1. Ayele B and Nenko GJMD. Treatment outcome of tuberculosis in selected health facilities of gedeo zone, southern ethiopia: A retrospective study. Mycobact Dis, 5(194):1–9, 2015.
    1. Bagcchi Sanjeet. WHO’s global tuberculosis report 2022. The Lancet Microbe, 4(1):e20, 2023. - PubMed

Publication types